Back to search

Article

Protocol for a phase 2, partially-blinded, randomised trial assessing the safety and efficacy of sorfequiline or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009)

2025-12-08

Abstract excerpt

<title>Abstract</title> <p> <bold>Introduction</bold> : In 2023, tuberculosis (TB) returned to being the world’s leading cause of death from a single infectious agent. Current standard of care for drug-sensitive tuberculosis (DS-TB) treatment has a long duration with risk of poor compliance and outcomes, and increased risk of development of resistant strains. Sorfequiline (S) is a second generation diarylquinol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6e55d974-6a97-560e-944f-cb7deac12be1
DOI
10.21203/rs.3.rs-7298866/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Protocol for a phase 2, partially-blinded, randomised trial assessing the safety and efficacy of sorfequiline or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009)DOI 10.21203/rs.3.rs-7298866/v1
Next Generation TB Drug Combinations from the Pan-TB Consortium: Combination Efficacy and Contributions of Individual Agents, Evaluated in a BALB/c Mouse TB ModelSemantic proximity
Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanidSemantic proximity
We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.Semantic proximity
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practiceSemantic proximity
Bedaquiline containing regimen showed excellent efficacy and safety for the treatment of pre-extensively drug-resistant tuberculosisSemantic proximity
Assessment of Pharmacotherapy and Clinical Outcomes of Treatment for the Development of Cardiovascular Disease among Tuberculosis PatientsSemantic proximity
Bedaquiline, pretomanid and linezolid in multidrug-resistant and pre-extensively drug-resistant tuberculosis in refugees from Ukraine and Somalia in GermanySemantic proximity
Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We StandSemantic proximity
The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis.Semantic proximity
Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in UgandaSemantic proximity
Treatment outcomes of drug-resistant <i>Mycobacterium tuberculosis</i> infection in Cameroon: a systematic review and meta-analysisSemantic proximity
TB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration.Semantic proximity
Select a neighboring publication to make it the new centre.